U.S. Post Operative Pain Management Market Size, Share & Forecast 2026–2032

ID: MR-11215 | Published: November 2026
Download PDF Sample

Report Highlights

  • ✓Country: United States
  • ✓Market: Post Operative Pain Management
  • ✓Market Size 2024: USD 5.9 billion
  • ✓Market Size 2032: USD 8.6 billion
  • ✓CAGR: 4.8%
  • ✓Base Year: 2025
  • ✓Forecast Period: 2026–2032
Market Growth Chart
Want Detailed Insights - Download Sample
Analyst Findings and Recommendations
FINDING 01
Non-opioid launches reshape formularies: Vertex's Journavx (suzetrigine), approved by the FDA in January 2025 as a non-opioid for moderate-to-severe acute pain, is entering hospital formularies that Pacira's Exparel has dominated for surgical infiltration. Pharmacy and therapeutics committees, not prescribers, will decide which product captures share.
FINDING 02
Stewardship raises spending per case: The consensus view that opioid stewardship shrinks the market is wrong. Tighter prescribing is moving spend toward premium liposomal and extended-release local anesthetics, lifting average drug cost per surgical case as ERAS protocols expand.
ANALYST RECOMMENDATION

Analyst Recommendation — Secure ASC reimbursement early: Specialty pharma and device investors should file ambulatory surgery center and Medicare Part B reimbursement strategies by Q3 2026, ahead of the CY2027 OPPS proposed rule. Ambulatory surgery centers will drive adoption, and pricing evidence determines which non-opioid products survive bundled-payment economics.

U.S. Post-Operative Pain: Market Overview

The U.S. post-operative pain management market generated an estimated USD 5.9 billion in 2024, making it the largest national pool of perioperative analgesic spending worldwide. Its structure departs from the global norm because prescribing is shaped by federal opioid stewardship rules rather than clinical preference alone. Hospitals, ambulatory surgery centers, and surgeons have shifted from opioid-heavy regimens toward multimodal protocols built on NSAIDs, acetaminophen, and long-acting local anesthetics.

Demand is anchored in tens of millions of annual surgical procedures and a growing share of elective orthopedic and gynecologic cases performed in outpatient settings. Hospital purchasing runs through group purchasing organizations and pharmacy and therapeutics committees, which control formulary access for premium non-opioid products. Pricing is set less by list price than by bundled reimbursement and negotiated contracts with large integrated delivery networks.

Growth Drivers in the U.S. Post-Operative Pain Market

First, an aging population sustains surgical volume. Adults aged 65 and older represent roughly 18 percent of Americans, and Medicare beneficiaries account for most total knee and hip replacements, procedures that require extended analgesia. Second, the Centers for Medicare and Medicaid Services has steadily expanded the ambulatory surgical center covered procedures list, moving higher-acuity orthopedic cases into settings where long-acting infiltration products are standard.

Third, the opioid stewardship framework itself creates demand. The CDC's 2022 Clinical Practice Guideline for Prescribing Opioids for Pain, the SUPPORT for Patients and Communities Act of 2018, and Joint Commission pain standards push clinicians toward opioid-sparing multimodal regimens. Vertex's suzetrigine approval in January 2025 further broadens the non-opioid pipeline supporting this shift.

Market Restraints and Entry Barriers

Entry is constrained by FDA approval pathways that require costly Phase 3 trials to support analgesic efficacy claims, and by hospital formulary reviews that take 12 to 18 months. Generic NSAIDs and acetaminophen are priced near zero, so new entrants must justify premium pricing against established alternatives using outcome data such as opioid consumption reduction and shorter length of stay.

Payment design is the second barrier. Medicare Part B reimburses separately billed drugs at average sales price plus a 6 percent add-on, while inpatient stays fall under diagnosis-related group bundles that absorb drug costs. Integrated delivery networks use group purchasing organizations such as Vizient and Premier to negotiate steep discounts, leaving little margin for undifferentiated products.

Market Opportunities in the United States

Near-term opportunities cluster in ambulatory surgery centers, where orthopedic and spine procedures are expanding fastest and where non-opioid regimens reduce discharge-related adverse events. Sustained-release local anesthetic systems suit ASC economics because they are administered once per case. Analyst estimates place the addressable outpatient orthopedic analgesic spend at roughly USD 1.2 billion annually, with unit drug costs of several hundred dollars per case.

A second opportunity lies in opioid-free discharge pathways. Opioid settlement funds, exceeding USD 50 billion nationally and distributed to states and municipalities through 2038, are financing prevention programs that include non-opioid pain protocols in community hospitals. Digital post-operative monitoring linked to pharmacy dispensing gives vendors a route into bundled-payment accountable care organizations.

Market at a Glance

MetricValue
Market Size 2024USD 5.9 billion
Market Size 2032USD 8.6 billion
Growth Rate (CAGR)4.8%
Most Critical Decision FactorFormulary access and bundled reimbursement eligibility
Largest RegionSouth Census Region
Competitive StructureModerately consolidated, with branded specialty players and generic manufacturers

Leading Market Participants

  • Pacira BioSciences
  • Vertex Pharmaceuticals
  • Heron Therapeutics
  • Pfizer
  • Fresenius Kabi
  • Hikma Pharmaceuticals
  • Baxter International
  • Teva Pharmaceuticals
  • Avanos Medical
  • Mallinckrodt Pharmaceuticals

Regulatory and Policy Environment

The FDA's Center for Drug Evaluation and Research reviews analgesic new drug applications, with a standard review goal of ten months after the 60-day filing period and six months under priority review. The DEA schedules opioid products under the Controlled Substances Act. The CDC's 2022 guideline is non-binding but is widely embedded in hospital policy and state prescribing limits. The SUPPORT Act of 2018 and NIH's HEAL Initiative direct research funding toward non-opioid analgesics.

CMS governs reimbursement through the Hospital Outpatient Prospective Payment System, the ambulatory surgical center payment system, and Medicare Part B average sales price rules, with annual rules published each fall in the Federal Register. Joint Commission pain standards and state prescription drug monitoring program mandates add further compliance layers. Companies should prepare for the CY2027 OPPS proposed rule comment period in mid-2026.

Long-Term Outlook for U.S. Post-Operative Pain Care

By 2032 the market is forecast to reach USD 8.6 billion, growing at a 4.8 percent CAGR from the 2025 base year. Growth will come mainly from outpatient surgery and from non-opioid products, as suzetrigine and extended-release local anesthetics secure formulary positions. The non-opioid share of hospital analgesic spending will rise materially over the forecast period.

Generic analgesic volume will flatten while premium non-opioid products capture incremental value. Competitive intensity will increase as Vertex, Pacira, and Heron compete on outcomes data in ASC and hospital formularies. Payers will require evidence of reduced opioid consumption before approving premium prices, and companies that secure bundled-payment inclusion will hold the decisive advantage.

Frequently Asked Questions

Generic and 505(b)(2) reformulations of established analgesics offer the lowest barrier because they rely on existing safety data. Entrants should prioritize delivery-format improvements that shorten infusion or extend duration.
The guideline is non-binding but shapes hospital policy, so products that reduce opioid consumption gain formulary preference. Positioning should quantify opioid-sparing outcomes in clinical data.
Ambulatory surgery center payment and Medicare Part B reimbursement are the most consequential pathways for growth. Bundled-payment inclusion determines whether hospitals and ASCs will adopt premium products.
Formulary reviews typically take 12 to 18 months from submission to decision. Early engagement with pharmacy and therapeutics committees shortens this timeline.
Settlement funds are directed to prevention and treatment programs that increasingly include non-opioid protocols. Vendors should target community hospital programs funded through state and municipal allocations.

Market Segmentation

By Drug Class
  • Opioid Analgesics
  • NSAIDs
  • Local Anesthetics
  • Acetaminophen
  • Novel Non-Opioid Analgesics
By Care Setting
  • Hospitals
  • Ambulatory Surgical Centers
  • Office-Based Surgical Practices
  • Home Care Settings
By Route of Administration
  • Oral
  • Intravenous
  • Infiltration and Nerve Block
  • Transdermal

Table of Contents

Chapter 01 Methodology and Scope
1.1 Research Methodology
1.2 Scope and Definitions
1.3 Data Sources
Chapter 02 Executive Summary
2.1 Report Highlights
2.2 Market Size and Forecast 2024-2032
Chapter 03 U.S. Post-Operative Pain - Market Analysis
3.1 Market Overview
3.2 Growth Drivers
3.3 Restraints
3.4 Opportunities
Chapter 04 Drug Class Insights
4.1 Opioid Analgesics
4.2 NSAIDs
4.3 Local Anesthetics
4.4 Novel Non-Opioid Analgesics
4.5 Others
Chapter 05 Care Setting Insights
5.1 Hospitals
5.2 Ambulatory Surgical Centers
5.3 Office-Based Surgical Practices
5.4 Home Care Settings
5.5 Others
Chapter 06 Route of Administration Insights
6.1 Oral
6.2 Intravenous
6.3 Infiltration and Nerve Block
6.4 Transdermal
6.5 Others
Chapter 07 Competitive Landscape
7.1 Market Players
7.2 Leading Market Participants
7.2.1 Pacira BioSciences
7.2.2 Vertex Pharmaceuticals
7.2.3 Heron Therapeutics
7.2.4 Pfizer
7.2.5 Fresenius Kabi
7.2.6 Hikma Pharmaceuticals
7.2.7 Baxter International
7.2.8 Teva Pharmaceuticals
7.2.9 Avanos Medical
7.2.10 Mallinckrodt Pharmaceuticals
7.3 Regulatory Environment
7.4 Outlook

Research Framework and Methodological Approach

Information
Procurement

Information
Analysis

Market Formulation
& Validation

Overview of Our Research Process

MarketsNXT follows a structured, multi-stage research framework designed to ensure accuracy, reliability, and strategic relevance of every published study. Our methodology integrates globally accepted research standards with industry best practices in data collection, modeling, verification, and insight generation.

1. Data Acquisition Strategy

Robust data collection is the foundation of our analytical process. MarketsNXT employs a layered sourcing model.

Secondary Research
  • Company annual reports & SEC filings
  • Industry association publications
  • Technical journals & white papers
  • Government databases (World Bank, OECD)
  • Paid commercial databases
Primary Research
  • KOL Interviews (CEOs, Marketing Heads)
  • Surveys with industry participants
  • Distributor & supplier discussions
  • End-user feedback loops
  • Questionnaires for gap analysis

Analytical Modeling and Insight Development

After collection, datasets are processed and interpreted using multiple analytical techniques to identify baseline market values, demand patterns, growth drivers, constraints, and opportunity clusters.

2. Market Estimation Techniques

MarketsNXT applies multiple estimation pathways to strengthen forecast accuracy.

Bottom-up Approach

Country Level Market Size
Regional Market Size
Global Market Size

Aggregating granular demand data from country level to derive global figures.

Top-down Approach

Parent Market Size
Target Market Share
Segmented Market Size

Breaking down the parent industry market to identify the target serviceable market.

Supply Chain Anchored Forecasting

MarketsNXT integrates value chain intelligence into its forecasting structure to ensure commercial realism and operational alignment.

Supply-Side Evaluation

Revenue and capacity estimates are developed through company financial reviews, product portfolio mapping, benchmarking of competitive positioning, and commercialization tracking.

3. Market Engineering & Validation

Market engineering involves the triangulation of data from multiple sources to minimize errors.

01 Data Mining

Extensive gathering of raw data.

02 Analysis

Statistical regression & trend analysis.

03 Validation

Cross-verification with experts.

04 Final Output

Publication of market study.

Client-Centric Research Delivery

MarketsNXT positions research delivery as a collaborative engagement rather than a static information transfer. Analysts work with clients to clarify objectives, interpret findings, and connect insights to strategic decisions.